These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1337430

  • 21. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK, Davey MW, Davey RA.
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [Abstract] [Full Text] [Related]

  • 22. In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells.
    Miyamoto H.
    Acta Med Okayama; 1986 Apr; 40(2):75-81. PubMed ID: 3012966
    [Abstract] [Full Text] [Related]

  • 23. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
    Fanciulli M, Valentini A, Bruno T, Citro G, Zupi G, Floridi A.
    Oncol Res; 1996 Apr; 8(3):111-20. PubMed ID: 8823807
    [Abstract] [Full Text] [Related]

  • 24. Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.
    Kiura K, Ohnoshi T, Tabata M, Shibayama T, Kimura I.
    Acta Med Okayama; 1993 Jun; 47(3):191-7. PubMed ID: 8104372
    [Abstract] [Full Text] [Related]

  • 25. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
    Basu A, Weixel K, Saijo N.
    Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
    [Abstract] [Full Text] [Related]

  • 26. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
    Yonei T, Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Moritaka T, Shibayama T, Tabata M, Segawa Y, Takigawa N.
    Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
    [Abstract] [Full Text] [Related]

  • 27. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996 Aug; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

  • 28. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
    Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I.
    Acta Med Okayama; 1992 Jun; 46(3):203-12. PubMed ID: 1354408
    [Abstract] [Full Text] [Related]

  • 29. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
    Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N.
    Anticancer Res; 1996 Jun; 16(6B):3387-95. PubMed ID: 9042196
    [Abstract] [Full Text] [Related]

  • 30. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
    Cole SP, Downes HF, Mirski SE, Clements DJ.
    Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
    [Abstract] [Full Text] [Related]

  • 31. Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): cross-resistance patterns.
    Beketić-Oresković L, Osmak M.
    Neoplasma; 1994 Feb; 41(3):171-6. PubMed ID: 7935986
    [Abstract] [Full Text] [Related]

  • 32. Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.
    Kiura K, Watarai S, Shibayama T, Ohnoshi T, Kimura I, Yasuda T.
    Anticancer Drug Des; 1993 Dec; 8(6):417-28. PubMed ID: 8286010
    [Abstract] [Full Text] [Related]

  • 33. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH, Lewis AD, Ehsan MN, Sikic BI.
    Cancer Res; 1991 Oct 01; 51(19):5181-7. PubMed ID: 1717140
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N.
    Anticancer Res; 1995 Oct 01; 15(2):393-8. PubMed ID: 7763011
    [Abstract] [Full Text] [Related]

  • 35. Antitumor activity of magainin analogues against human lung cancer cell lines.
    Ohsaki Y, Gazdar AF, Chen HC, Johnson BE.
    Cancer Res; 1992 Jul 01; 52(13):3534-8. PubMed ID: 1319823
    [Abstract] [Full Text] [Related]

  • 36. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
    Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H, Ohnoshi T, Tanimoto M.
    Anticancer Res; 2004 Jul 01; 24(6):3911-6. PubMed ID: 15736431
    [Abstract] [Full Text] [Related]

  • 37. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
    Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N.
    J Natl Cancer Inst; 1992 Jan 15; 84(2):113-8. PubMed ID: 1310509
    [Abstract] [Full Text] [Related]

  • 38. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.
    Takigawa N, Takeyama M, Shibayama T, Tada A, Kawata N, Okada C, Aoe K, Kozuki T, Hotta K, Tabata M, Kiura K, Ueoka H, Tanimoto M, Takahashi K.
    Oncol Rep; 2006 Apr 15; 15(4):837-42. PubMed ID: 16525668
    [Abstract] [Full Text] [Related]

  • 39. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
    Nokihara H, Yano S, Nishioka Y, Hanibuchi M, Higasida T, Tsuruo T, Sone S.
    Jpn J Cancer Res; 2001 Jul 15; 92(7):785-92. PubMed ID: 11473730
    [Abstract] [Full Text] [Related]

  • 40. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H, Tabata M, Kiura K, Ueoka H, Kawata K, Chikamori M, Aoe K, Chikamori K, Matsushita A, Harada M.
    Clin Cancer Res; 2002 Jan 15; 8(1):287-92. PubMed ID: 11801571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.